Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare

Authors:

Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) with an incidence rate of about 6 per 100,000 in the general United States (U.S.) population, and an e...
Funding Information
  • Pfizer

This publication has 25 references indexed in Scilit: